From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Inhaled Therapy and Mortality in COPD

Combination therapy with fluticasone plus salmeterol was associated with reduced mortality, but the difference was just short of statistical significance.

It is unclear whether inhaled corticosteroids and long-acting ß-agonists reduce mortality in patients with chronic obstructive pulmonary disease. In this industry-sponsored international trial (known as TORCH), researchers randomized more than 6000 COPD patients to receive inhaled salmeterol plus fluticasone (Advair 50/500), salmeterol (Serevent) alone, fluticasone (Flovent) alone, or placebo — all given twice daily. Enrollment criteria included a history of smoking, FEV1 <60% of predicted, and reversibility with albuterol that was less than 10% of the patient's predicted FEV1.

At 3 years, the following outcomes were noted:

  • All-cause mortality (the primary endpoint) was 12.6% with combined therapy, 13.5% with salmeterol, 16.0% with fluticasone, and 15.2% with placebo. The difference between combined therapy and placebo did not quite reach significance (P=0.052).
  • Combined therapy and salmeterol alone, but not fluticasone alone, significantly reduced the rate of hospitalization for COPD exacerbation.
  • Pneumonia occurred more frequently in the two groups receiving fluticasone (about 19%) than in the placebo or salmeterol-alone groups (about 13%).
  • Combined therapy was superior to both monotherapies — which, in turn, were superior to placebo — in reducing the number of moderate or severe COPD exacerbations and in mitigating the declines in FEV1 and health status scores.

Comment: In this study of COPD patients, inhaled therapy with fluticasone plus salmeterol was associated with a 2.6 percentage-point reduction in mortality that just failed to reach statistical significance. In several respects, salmeterol monotherapy appeared superior to fluticasone monotherapy — an interesting outcome given the current controversy about potential harms with long-acting ß-agonists in asthma. How to interpret this trial will be debated for some time; for now, an editorialist concludes that combination therapy offers several advantages (but not clear-cut mortality reduction), that steroid monotherapy "should not be advocated," that salmeterol monotherapy "appears to be safe," and that the increased incidence of pneumonia with fluticasone requires further investigation.

— Allan S. Brett, MD

Published in Journal Watch General Medicine February 21, 2007

Citation(s):

Calverley PMA et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356:775-89.

Rabe KF. Treating COPD — The TORCH trial, P values, and the dodo. N Engl J Med 2007 Feb 22; 356:851-4.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Related Content

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.